Use of antifungal agents in pediatric and adult high-risk areas

  • E. Ramírez
  • J. García-Rodríguez
  • A. M. Borobia
  • J. M. Ortega
  • S. Lei
  • A. Barrios-Fernández
  • M. Sánchez
  • A. J. Carcas
  • A. Herrero
  • J. M. de la Puente
  • J. Frías


The purpose of this investigation was to describe the characteristics of the use of systemic antifungal agents (AFAs) and to evaluate their appropriateness of use. A prospective drug-utilisation study was conducted in intensive-care areas: haematology-oncology services and transplant units. Data were collected in three periods over 9 months. The required sample size was determined to be 113 patients (margin of error ±7%, 95% confidence interval [CI]), assuming a variability of 50%. Two different investigator groups evaluated the appropriateness of use separately; Cohen’s Kappa index was used to calculate the degree of agreement between groups. A total of 114 patients we included, of which 62 (54.4%) were children. A total of 150 prescriptions were administered; fluconazole was the most frequently prescribed (38%), followed by liposomal amphotericin B (22.7%) and caspofungin (18.7%). The indications were: (1) pre-emptive treatment of Candida in non-neutropaenic critically ill patients (35.1%), (2) treatment of systemic fungal infection (24.6%), (3) prophylaxis for systemic fungal infection (SFI) in immunocompromised patients (16.7%), (4) prophylaxis of SFI in transplant recipients (12.3%), (5) prophylaxis of SFI in preterm infants (5.3%), (6) treatment of SFI in neonates (6.1%). The Kappa index showed a substantial agreement (Kappa = 0.73). The indications were considered to be inappropriate in 71 (47.3%) episodes. The indications or dosages were inappropriate in 79 cases (52.7%). The indications, dosages or duration of treatment were inappropriate in 83 cases (55.3%). We conclude that AFAs are prescribed for a significant number of inappropriate indications.


  1. 1.
    Vartivarian SE, Anaissie EJ, Bodey GP (1993) Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis 17(suppl 2):S487–S491PubMedCrossRefGoogle Scholar
  2. 2.
    Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554PubMedCrossRefGoogle Scholar
  3. 3.
    Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332PubMedCrossRefGoogle Scholar
  4. 4.
    Hadley S, Karchmer AW (1995) Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 9:1045–1074PubMedGoogle Scholar
  5. 5.
    Wingard JR (1999) Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 5:55–68PubMedCrossRefGoogle Scholar
  6. 6.
    Williamson EC, Millar MR, Steward CG, Cornish JM, Foot AB, Oakhill A, Pamphilon DH, Reeves B, Caul EO, Warnock DW, Marks DI (1999) Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 104:560–568PubMedCrossRefGoogle Scholar
  7. 7.
    Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, Blumberg HM, Patterson JE, Rinaldi M, Edwards JE, Wenzel RP, Jarvis W (2000) Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 19:319–324PubMedCrossRefGoogle Scholar
  8. 8.
    Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP; National Epidemiology of Mycoses Survey (NEMIS) Study Group (2001) Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33:177–186PubMedCrossRefGoogle Scholar
  9. 9.
    Antinori S, Nebuloni M, Magni C, Fasan M, Adorni F, Viola A, Corbellino M, Galli M, Vago G, Parravicini C, Ridolfo AL (2009) Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: a retrospective study of 1,630 autopsies performed between 1984 and 2002. Am J Clin Pathol 132(2):221–227PubMedCrossRefGoogle Scholar
  10. 10.
    Chandrasekar PH, Alangaden G, Manavathu E (2000) Aspergillus: an increasing problem in tertiary care hospitals? Clin Infect Dis 30:984–985PubMedCrossRefGoogle Scholar
  11. 11.
    Dixon S, McKeen E, Tabberer M, Paisley S (2004) Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics 22(7):421–433PubMedCrossRefGoogle Scholar
  12. 12.
    de With K, Steib-Bauert M, Knoth H, Dörje F, Strehl E, Rothe U, Maier L, Kern WV (2005) Hospital use of systemic antifungal drugs. BMC Clin Pharmacol 5(1):1PubMedCrossRefGoogle Scholar
  13. 13.
    Alonso S, Arribi A, Vergas J, Martín MC, Arce B, Terleira A, Portolés A (2009) Estudio piloto de utilización de antifúngicos sistémicos en el Hospital Clínico San Carlos. Propuesta de un método de estúdio. Rev Esp Quimioter 22(3):127–134PubMedGoogle Scholar
  14. 14.
    Modified Karch–Lasagna algorithm. Spanish Pharmacovigilance System. In: Aguirre, C. Causalidad en Farmacovigilancia. In: Rodríguez, J.M., Aguirre, C. (Eds.) Pharmacovigilancia. Bibao: Servicio Editorial de la Universidad del País Vasco, pp 93–98Google Scholar
  15. 15.
    Meunier F, Lukan C (2008) The First European Conference on Infections in Leukaemia—ECIL1: a current perspective. Eur J Cancer 44:2112–2117PubMedCrossRefGoogle Scholar
  16. 16.
    Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik J-A, Wingard JR, Patterson TF; Infectious Diseases Society of America (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360PubMedCrossRefGoogle Scholar
  17. 17.
    Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Krüger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94(1):113–122PubMedCrossRefGoogle Scholar
  18. 18.
    Rowe JM, Ciobanu N, Ascensao J, Stadtmauer EA, Weiner RS, Schenkein DP, McGlave P, Lazarus HM (1994) Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG). Ann Intern Med 120(2):143–158PubMedGoogle Scholar
  19. 19.
    Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious Diseases Society of America. Clin Infect Dis 48:503–535PubMedCrossRefGoogle Scholar
  20. 20.
    León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Álvarez-Lerma F, Garnacho-Montero J, León MA; EPCAN Study Group (2006) A bedside scoring system (“Candida score”) for early antifungal treatment in non-neutropenic critically ill patients with Candida colonization. Crit Care Med 34(3):730–737PubMedCrossRefGoogle Scholar
  21. 21.
    Protocolo de diagnóstico y tratamiento de infección fúngica invasora en pacientes críticos en UCI. Hospital Universitario 12 de Octubre. Madrid. Versión 1. Septiembre 2007Google Scholar
  22. 22.
    Almirante B, Rodríguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P, Fridkin SK, Morgan J, Rodriguez-Tudela JL, Warnock DW, Pahissa A; Barcelona Candidemia Project Study Group (2005) Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43:1829–1835PubMedCrossRefGoogle Scholar
  23. 23.
    Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J, Lee-Yang W, Ciblak MA, Benjamin LE, Sanza LT, Huie S, Yeo SF, Brandt ME, Warnock DW (2004) Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42(4):1519–1527PubMedCrossRefGoogle Scholar
  24. 24.
    Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37:1172–1177PubMedCrossRefGoogle Scholar
  25. 25.
    Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, Pfaller MA (2002) Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 40:1298–1302PubMedCrossRefGoogle Scholar
  26. 26.
    Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24:1122–1128PubMedCrossRefGoogle Scholar
  27. 27.
    Slotman GJ, Burchard KW (1987) Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 122(2):147–151PubMedCrossRefGoogle Scholar
  28. 28.
    Nguyen MH, Peacock JE Jr, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, Wagener MM, Yu VL (1995) Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 155:2429–2435PubMedCrossRefGoogle Scholar
  29. 29.
    Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, Hiramatsu Y, Nitenberg G, Nyström PO, Pittet D, Rogers T, Sandven P, Sganga G, Schaller MD, Solomkin J (1998) Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 24(3):206–216PubMedCrossRefGoogle Scholar
  30. 30.
    Prieto Yerro C, Laredo Velasco L, Rodríguez Bernardino Á, Vargas Castrillón E, Ambit Ávila MI, Merchante Medina A (2001) Modificación en el patrón de uso de anfotericina B no convencional tras la puesta en marcha de una intervención formativa en el Hospital Clínico San Carlos de Madrid. Rev Esp Salud Pública 75:353–360PubMedCrossRefGoogle Scholar
  31. 31.
    Powers JH, Dixon CA, Goldberger MJ (2002) Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 346:289–290PubMedCrossRefGoogle Scholar
  32. 32.
    Garey KW, Pai MP, Suda KJ, Turpin RS, Rege MD, Mingo DE, Bearden DT (2007) Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 16:919–927PubMedCrossRefGoogle Scholar
  33. 33.
    White MH (1997) The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis 24:1129–1130PubMedCrossRefGoogle Scholar
  34. 34.
    Vehreschild JJ, Böhme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G, Drzisga I, Cornely OA (2007) A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 55:445–449PubMedCrossRefGoogle Scholar
  35. 35.
    Playford EG, Webster AC, Sorrell TC, Craig JC (2004) Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev (3):CD004291Google Scholar
  36. 36.
    Winston DJ, Busuttil RW (2002) Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 74(5):688–695PubMedCrossRefGoogle Scholar
  37. 37.
    Cai CJ, Yi SH, Guo Y, Li MR, Yi HM, Yang Y, Lu MQ, Chen GH (2007) The impact of itraconazole versus fluconazole on the prevention of postoperative invasive fungal infections after orthotopic liver transplantation. Zhonghua Nei Ke Za Zhi 46(11):911–913PubMedGoogle Scholar
  38. 38.
    Playford EG, Webster AC, Sorrell TC, Craig JC (2006) Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 25(9):549–561PubMedCrossRefGoogle Scholar
  39. 39.
    Castroagudín JF, Pontón C, Bustamante M, Otero E, Martínez J, Tomé S, Conde R, Segade FR, Delgado M, Brage A, Galbán C, Varo E (2005) Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc 37(9):3965–3967PubMedCrossRefGoogle Scholar
  40. 40.
    Clerihew L, McGuire W (2004) Systemic antifungal drugs for invasive fungal infection in preterm infants. Cochrane Database Syst Rev (1):CD003953Google Scholar
  41. 41.
    Austin NC, Darlow B (2004) Prophylactic oral antifungal agents to prevent systemic Candida infection in preterm infants. Cochrane Database Syst Rev (1):CD003478Google Scholar
  42. 42.
    Manzoni P, Arisio R, Mostert M, Leonessa M, Farina D, Latino MA, Gomirato G (2006) Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Paediatrics 117(1):e22–e32CrossRefGoogle Scholar
  43. 43.
    Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK Jr, Sullivan JE, Ramey N, Jayaraman B, Hoppu K, Adamson PC, Gastonguay MR, Barrett JS; National Institute of Child Health and Development Pediatric Pharmacology Research Unit Network (2008) Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 52(11):4043–4049PubMedCrossRefGoogle Scholar
  44. 44.
    Juster-Reicher A, Leibovitz E, Linder N, Amitay M, Flidel-Rimon O, Even-Tov S, Mogilner B, Barzilai A (2000) Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 28:223–226PubMedCrossRefGoogle Scholar
  45. 45.
    Yang BH, Peng MY, Hou SJ, Sun JR, Lee SY, Lu JJ (2009) Fluconazole-resistant Kodamaea ohmeri fungemia associated with cellulitis: case report and review of the literature. Int J Infect Dis 13(6):e493–e497PubMedCrossRefGoogle Scholar
  46. 46.
    World Health Organization (WHO) (2003) Introduction to drug utilization research. WHO, GenevaGoogle Scholar
  47. 47.
    Meyer E, Schwab F, Gastmeier P, Ruden H, Heininger A (2007) Antifungal use in intensive care units. J Antimicrob Chemother 60(3):619–624PubMedCrossRefGoogle Scholar
  48. 48.
    Cars O, Ekdahl K (2002) SWEDRES 2002. A report on Swedish antibiotic utilisation and resistance in human medicine. The Swedish Strategic Programme for the Rational Use of Antimicrobial Agents (STRAMA) and the Swedish Institute for Infectious Disease Control, Stockholm, pp 1–36Google Scholar
  49. 49.
    Grau S, Torres-Rodríguez JM, Monterde J (1996) Situación actual de las infecciones por hongos: ¿Son las anfotericinas lipídicas la panacea? Farm Hosp 20:390–392Google Scholar
  50. 50.
    Ericsson O, Hallmen AC, Wikstrom I (1996) Amphotericin B is incompatible with lipid emulsions. Ann Pharmacother 30:298PubMedGoogle Scholar
  51. 51.
    Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA; Micafungin Invasive Candidiasis Working Group (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369(9572):1519–1527PubMedCrossRefGoogle Scholar
  52. 52.
    Rex JH, Lozano-Chiu M, Paetznik V and co-investigaors of the NIAID MSG Candidiasis Subproject (1998) Susceptibility testing of current Candida bloodstream isolates from Mycoses Study Group (MSG) Collaborative Study #34: isolates of C. krusei are often resistant to both fluconazole and amphotericin B [abstract 324]. In: Program and abstract of 36th Annual Meeting of Infectious Diseases Society of America (Denver): 136Google Scholar
  53. 53.
    European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) (2008) EUCAST technical Note on fluconazole. Clin Microbiol Infect 14:193–195CrossRefGoogle Scholar
  54. 54.
    Nucci M (2003) Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 16:607–612PubMedCrossRefGoogle Scholar
  55. 55.
    Voriconazole Spanish summary of product characteristics (available at:, last accessed September 28, 2010)
  56. 56.
    Marty FM, Cosimi LA, Baden LR (2004) Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350:950–952PubMedCrossRefGoogle Scholar
  57. 57.
    Zonios DI, Bennett JE (2008) Update on azole antifungals. Semin Respir Crit Care Med 29(2):198–210PubMedCrossRefGoogle Scholar
  58. 58.
    Cook PP, Catrou PG, Christie JD, Young PD, Polk RE (2004) Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother 53:853–859PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • E. Ramírez
    • 1
  • J. García-Rodríguez
    • 2
  • A. M. Borobia
    • 1
  • J. M. Ortega
    • 3
  • S. Lei
    • 1
  • A. Barrios-Fernández
    • 2
  • M. Sánchez
    • 3
  • A. J. Carcas
    • 1
  • A. Herrero
    • 3
  • J. M. de la Puente
    • 4
  • J. Frías
    • 1
  1. 1.Clinical Pharmacology ServiceHospital Universitario La Paz, IdiPAZ, School of Medicine, Universidad Autónoma de MadridMadridSpain
  2. 2.Microbiology ServiceHospital Universitario La Paz, IdiPAZMadridSpain
  3. 3.Pharmacy ServiceHospital Universitario La Paz, IdiPAZMadridSpain
  4. 4.Medical SubdirectionHospital Universitario La Paz, IdiPAZMadridSpain

Personalised recommendations